Acetyl Hexapeptide-8 616204-22-9

98% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	Acetyl Hexapeptide-8
CAS No.	616204-22-9
Synonyms	Acetyl hexapeptide-3, Acetyl Hexapeptide-8 ，Arglinge
Sequence	Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2
Molecular Formula	C34H60N14O12S
Molecular Weight	888.9
Quality Standard	98% up by HPLC, Cosmetic grade
Appearance	White powder or transparent liquid

COA of Acetyl Hexapeptide-8

Items	Specifications	Results
Appearance	White Powder	Comforms
Peptide Purity (by HPLC)	≥95.0% by area integration	99.20%
Water Content (Karl Fischer)	≤5.0%	3.9%
Acetate Content (HPLC)	≤15.0%	6.80%
Identity by MS	888.42±1	888.9
Solubility	Soluble in water or 1% acetate acid	Conforms
PH	3.5-6.5	6.0
Amino Acid Composition	±10% of theoretical	Conforms
Assay	≥ 98%	99.5%
Conclusion	Meet the specification of enterprise standard

Usage

Acetyl hexapeptide-8/Acetyl hexapeptide-3(Argireline) is a synthetic anti-wrinkle cosmetics ingredient. It is a peptide which is a fragment of SNAP-25, a substrate of Botulinum toxin .Argireline is used in attempts to decrease the visible effects of aging by reducing the deep wrinkles and lines that occur around the forehead and eyes.Chemically, when applied as a solution to specific areas of the face, Argireline inhibits the reactions that cause muscles to move or contract – for example when forming facial expressions such as smiling or frowning.

Function of Palmitoyl Tetrapeptide-8

Acetyl Hexapeptide-8 is a high-quality anti-wrinkle cosmetic raw material with high anti-wrinkle activity and low side effects,and has been used in various high-end cosmetics series. It can locally block nerves from transmitting muscle contraction messages, affect skin nerve conduction, relax facial muscles, and smooth out dynamic lines, static lines and fine lines; effectively reorganize collagen elasticity, increase the activity of elastin, and make the face Lines relax and wrinkles are smoothed to improve relaxation. For details:

1. Increase type I collagen
2. Increase type IV collagen
3. Increased laminin-5
4. Increase the integration of protein
5. To promote the differentiation of epidermal cells mature
6. To promote skin regeneration
7. To reduce wrinkles

Application of Palmitoyl Tetrapeptide-8

1. Acetyl Hexapeptide-8 stimulates hair pigmentation and reverses the gray hair process.
2. Acetyl Hexapeptide-8 induces skin pigmentation.
3. Acetyl Hexapeptide-8 strengthens the skin’s defenses against harmful effects of UV.
4. Acetyl Hexapeptide-8 reduces skin erythema.
5. Acetyl Hexapeptide-8 protects and repairs DNA damage caused by UV exposure (UVA & UVB).
6. Acetyl Hexapeptide-8 reduces the inflammatory response.

Hot Tags : acetyl hexapeptide for cosmetics acetyl hexapeptide-8 powder Argireline powder Hexapeptide Polypeptide powder Cosmetic Polypeptide

Send A Message

Related Products

LIRAGLUTIDE 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.